Cargando…

Minimum inhibitory concentration, pharmacokinetics/pharmacodynamics and therapeutic drug monitoring: An integrated approach for multidrug-resistant tuberculosis

Detalles Bibliográficos
Autor principal:	Srivastava, Shashikant
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2015
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4502212/ https://www.ncbi.nlm.nih.gov/pubmed/26180397

Ejemplares similares

Determination of minimum inhibitory and minimum bactericidal concentrations of Brazilian strains of Leptospira spp. for streptomycin sulphate
por: Rocha, Bruno Ribeiro, et al.
Publicado: (2020)

Minimum inhibitory concentrations of rifampin and isoniazid among multidrug and isoniazid resistant Mycobacterium tuberculosis in Ethiopia
por: Getahun, Muluwork, et al.
Publicado: (2022)

Pharmacokinetics and pharmacodynamics of anti-tuberculosis drugs: An evaluation of in vitro, in vivo methodologies and human studies
por: Alffenaar, Jan-Willem C., et al.
Publicado: (2022)

Correlation of gyr Mutations with the Minimum Inhibitory Concentrations of Fluoroquinolones among Multidrug-Resistant Mycobacterium tuberculosis Isolates in Bangladesh
por: Uddin, Mohammad Khaja Mafij, et al.
Publicado: (2021)

Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea
por: Yang, Jeong Seong, et al.
Publicado: (2018)

Integrating Pharmacokinetics and Pharmacodynamics in Operational Research to End Tuberculosis
por: Alffenaar, Jan-Willem C, et al.
Publicado: (2020)

Therapeutic Drug Monitoring and Individualized Medicine of Dasatinib: Focus on Clinical Pharmacokinetics and Pharmacodynamics
por: He, Shiyu, et al.
Publicado: (2021)

Minimal inhibitory concentrations of first-line drugs of multidrug-resistant tuberculosis isolates
por: Schönfeld, Nicolas, et al.
Publicado: (2012)

Erratum: Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea
Publicado: (2019)

Plasma concentrations of second-line antituberculosis drugs in relation to minimum inhibitory concentrations in multidrug-resistant tuberculosis patients in China: a study protocol of a prospective observational cohort study
por: Davies Forsman, Lina, et al.
Publicado: (2018)

Pharmacodynamic comparison of different antimicrobial regimens against Staphylococcus aureus bloodstream infections with elevated vancomycin minimum inhibitory concentration
por: da Costa, Thaina Miranda, et al.
Publicado: (2020)

Longitudinal Pharmacokinetic-Pharmacodynamic Biomarkers Correlate With Treatment Outcome in Drug-Sensitive Pulmonary Tuberculosis: A Population Pharmacokinetic-Pharmacodynamic Analysis
por: Kloprogge, Frank, et al.
Publicado: (2020)

Integration of pharmacometabolomics with pharmacokinetics and pharmacodynamics: towards personalized drug therapy
por: Kantae, Vasudev, et al.
Publicado: (2016)

Competence Mining of Vancomycin (VAN) in the Management of Infections Due to Bacterial Strains With High VAN Minimum Inhibitory Concentrations (MICs): A Novel Dosing Strategy Based on Pharmacokinetic/Pharmacodynamic Modeling
por: Song, Xiangqing, et al.
Publicado: (2021)

Pharmacodynamic Parameters of Pharmacokinetic/Pharmacodynamic (PK/PD) Integration Models
por: Zhang, Longfei, et al.
Publicado: (2022)

Cycloserine Population Pharmacokinetics and Pharmacodynamics in Patients with Tuberculosis
por: Alghamdi, Wael A., et al.
Publicado: (2019)

Linking minimum inhibitory concentrations to whole genome sequence-predicted drug resistance in Mycobacterium tuberculosis strains from Romania
por: Ruesen, Carolien, et al.
Publicado: (2018)

Sub-minimum inhibitory concentration of rifampin: a potential risk factor for resuscitation of Mycobacterium tuberculosis
por: Pourazar Dizaji, Shahin, et al.
Publicado: (2017)

The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of silver nanoparticles against Staphylococcus aureus
por: Parvekar, Prashik, et al.
Publicado: (2020)

Rifampin Pharmacokinetics/Pharmacodynamics in the Hollow-Fiber Model of Mycobacterium kansasii Infection
por: Srivastava, Shashikant, et al.
Publicado: (2022)

Therapeutic drug monitoring: linezolid too?
por: Richards, Guy A, et al.
Publicado: (2014)

Pharmacokinetic and Pharmacodynamic Considerations in the Design of Therapeutic Antibodies
por: Leipold, Douglas, et al.
Publicado: (2018)

Therapeutic Drug Monitoring in Non-Tuberculosis Mycobacteria Infections
por: Alffenaar, Jan-Willem, et al.
Publicado: (2021)

The Threat of Multidrug-resistant Tuberculosis
por: Paul, Rudrajit
Publicado: (2018)

High Variability in Isavuconazole Unbound Fraction in Clinical Practice: A Call to Reconsider Pharmacokinetic/Pharmacodynamic Targets and Breakpoints
por: Jansen, Anouk M. E., et al.
Publicado: (2023)

Author’s Reply to Srinivas: “Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection”
por: Namour, Florence
Publicado: (2015)

Pharmacokinetic, pharmacodynamic, and pharmacogenetic assays to monitor clopidogrel therapy
por: Alvitigala, Bhawani Yasassri, et al.
Publicado: (2020)

Population Pharmacokinetic and Concentration-QTc Analysis of Delamanid in Pediatric Participants with Multidrug-Resistant Tuberculosis
por: Sasaki, Tomohiro, et al.
Publicado: (2022)

Chronopharmacology in Therapeutic Drug Monitoring—Dependencies between the Rhythmics of Pharmacokinetic Processes and Drug Concentration in Blood
por: Dobrek, Lukasz
Publicado: (2021)

Whole Genome Sequencing Results Associated with Minimum Inhibitory Concentrations of 14 Anti-Tuberculosis Drugs among Rifampicin-Resistant Isolates of Mycobacterium Tuberculosis from Iran
por: Kardan-Yamchi, Jalil, et al.
Publicado: (2020)

The Minimum Inhibitory Concentration of Antibiotics: Methods, Interpretation, Clinical Relevance
por: Kowalska-Krochmal, Beata, et al.
Publicado: (2021)

Evaluation of clinicians’ knowledge and use of minimum inhibitory concentration values
por: Witt, Lucy S, et al.
Publicado: (2021)

Therapeutic Drug Monitoring Is a Feasible Tool to Personalize Drug Administration in Neonates Using New Techniques: An Overview on the Pharmacokinetics and Pharmacodynamics in Neonatal Age
por: De Rose, Domenico Umberto, et al.
Publicado: (2020)

What Is the Best Vancomycin Therapeutic Drug Monitoring Parameter to Assess Efficacy? A Critical Review of Experimental Data and Assessment of the Need for Individual Patient Minimum Inhibitory Concentration Value
por: Dalton, Bruce R.
Publicado: (2023)

“Quantitative Pharmacology: An introduction to integrative pharmacokinetic-pharmacodynamic analysis”
por: Lowe, P J
Publicado: (2012)

Proteomics of multidrug resistant Mycobacterium tuberculosis clinical isolates: A peep show on mechanism of drug resistance & perhaps more
por: Parsa, Kishore, et al.
Publicado: (2015)

Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC) for Twelve Antimicrobials (Biocides and Antibiotics) in Eight Strains of Listeria monocytogenes
por: Rodríguez-Melcón, Cristina, et al.
Publicado: (2021)

Pharmacokinetic and Pharmacodynamic Drug–Drug Interactions: Research Methods and Applications
por: Sun, Lei, et al.
Publicado: (2023)

Incorporating pharmacodynamic considerations into caffeine therapeutic drug monitoring in preterm neonates
por: Yu, Tian, et al.
Publicado: (2016)

Population Pharmacokinetic and Pharmacodynamic Analysis of Dalbavancin for Long-Term Treatment of Subacute and/or Chronic Infectious Diseases: The Major Role of Therapeutic Drug Monitoring
por: Cojutti, Pier Giorgio, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vnff1nqj212cfu5ch8cdd6lrtp